About
About Guanhao Biotech Co.,Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addition, it offers artificial lens and medical instruments; and cell technology services. Its products can be used in neurosurgery, thoracic general surgery, ophthalmology, dermatology, orthopedics, cosmetology, plastic surgery, and other areas. Guanhao Biotech Co.,Ltd. was founded in 1999 and is headquartered in Guangzhou, China.
Visit company website
5 years, 5 months ago
Guanhao Biotech Co.,Ltd is currently in a long term downtrend where the price is trading 13.7% below its 200 day moving average.
From a valuation standpoint, the stock is 19.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.5.
Guanhao Biotech Co.,Ltd's total revenue sank by 1.5% to $118M since the same quarter in the previous year.
Its net income has increased by 102.0% to $10M since the same quarter in the previous year.
Finally, its free cash flow fell by 59.4% to $38M since the same quarter in the previous year.
Based on the above factors, Guanhao Biotech Co.,Ltd gets an overall score of 1/5.